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KEY POINTS 
• miR-125b is epigenetically silenced in B cells. 
• Physiological silencing of miR-125b is required for normal B cell development. 
 
ABSTRACT 
Deregulation of several microRNAs can influence critical developmental checkpoints during hematopoiesis as 
well as cell functions, eventually leading to the development of autoimmune disease or cancer.  We found that 
miR-125b is expressed in bone marrow multipotent progenitors and myeloid cells but is shut down in the B cell 
lineage, and the gene encoding miR-125b lacked transcriptional activation markers in B cells.  To understand 
the biological importance of the physiological silencing of miR-125b expression in B cells, we drove its 
expression in the B cell lineage and found that dysregulated miR-125b expression impaired egress of immature 
B cells from the bone marrow to peripheral blood.  Such impairment appeared to be mediated primarily by 
inhibited expression of the sphingosine-1-phosphate receptor 1 (S1PR1).  Enforced expression of S1PR1 or 
CRISPR/Cas9-mediated genome editing of the miR-125b targeting site in the S1PR1 3’UTR rescued the miR-
125b-mediated defect in B cell egress. In addition to impaired B cell egress, miR-125b dysregulation initially 
reduced pre-B cell output, but later induced pre-B cell lymphoma/leukemia in mice. Genetic deletion of IRF4 
was found in miR-125b induced-B cell cancer but its role in oncogenic miR-125b-induced B cell transformation 
is still unknown.  Here, we further demonstrated an interaction of the effects of miR-125b and IRF4 in cancer 
induction by showing that miR125b-induced B cell leukemia was greatly accelerated in the IRF4 homozygous 
mutant mice. Thus, we conclude that physiological silencing of miR-125b is required for normal B cell 
development and also acts as a mechanism of cancer suppression. 
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INTRODUCTION  
B cells produce antibodies that react with foreign antigens and can help eliminate pathogenic invaders.  Early B 
cell development in the bone marrow is tightly controlled by multiple transcription factors, including PU.1, 
E2A, Pax5 and EBF11. Several factors, including sphingosine-1-phosphate receptor 1 (S1PR1), have been 
shown to mediate B cell egress from bone marrow 2-5.  
Mature miR-125b is encoded in two different genomic regions: miR-125b-1 is located on chromosomes 11 
and 9 in the human and mouse genomes, respectively; miR-125b-2 located on human chromosome 21 and 
mouse chromosome 16 6.  Dysregulated miR-125b expression has been found in many neoplastic blood 
disorders, including B-cell precursor acute lymphoblastic leukemia (BCP-ALL) 6, suggesting that miR-125b 
might act as an oncomiR able to transform cells by targeting genes involved in tumorigenesis.  Indeed, 
overexpression of miR-125b alone in mice is sufficient to induce tumors in multiple hematopoietic lineages 
generating myeloid, T cell and B cell leukemias 7-11.  Several target genes have been identified and postulated to 
have a role in the oncogenic properties of overexpressed miR-125b, such as Trp53inp1 and MAP3K11, which 
facilitate cell survival 8,12.  A genetic deletion of the gene encoding IRF4 has also been reported in miR-125b 
dysregulation-induced B cells 11.   In addition to promoting leukemia, several in vitro studies also suggest a role 
for this microRNA in B cell development and differentiation.  For instance, overexpression of miR-125b in 
primary B cells impairs LPS induction of these cells into plasma cells in vitro 13.  Despite these findings, the role 
of miR-125b in the early stages of B cell development in vivo and the underlying molecular mechanism of 
oncomiR miR-125b in B cell tumorigenesis are largely unknown. 
In this study, we found miR-125b is epigenetically silenced during the development of normal B cells. To 
examine the biological importance of the physiological silencing of miR-125b expression in the B cell lineage, 
we used transgenic (Tg) mice that overexpress miR-125b under the control of the Ig intronic enhancer Eμ. We 
found that B cell-specific miR-125b expression results in impaired release of immature B cells from the bone 
marrow into the blood.  We identified S1PR1 as a target of miR-125b in B cells and showed that enforced 
expression of S1PR1 or CRISPR/CAS9-mediated genome editing of the miR-125b binding site within the 
S1PR1 3’UTR rescues the egress defect resulting from miR-125b dysregulation.  In addition to impaired B cell 
egress, miR-125b dysregulation initially reduces pre-B cell output but later induces pre-B cell 
lymphoma/leukemia.  Genetic deletion of IRF4 was found in miR-125b-induced B cell cancer but its role in 
oncogenic miR-125b-induced B cell transformation is still unknown.  Here, we further demonstrated an 
interaction of the effects of miR-125b and IRF4 in cancer induction by showing that miR-125b-induced B cell 
leukemia is greatly accelerated in IRF4 homozygous mutant mice. Thus, we have uncovered a novel role for 
miR-125b as a negative regulator of early B cell development and conclude that epigenetic silencing of miR-
125b is required for normal B cell development. 
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METHODS 
Animals 
All mice were maintained in the Caltech Office of Laboratory Animal Resources (OLAR) facility (all protocols 
were in accordance to the rules and regulations of the Institutional Animal Care and Use Committee of 
California Institute of Technology).   
DNA constructs 
For luciferase assays, the microRNA-125b expression cassette was subcloned into the pMG vector. The 3’UTR 
of S1PR1 containing the miR-125b-binding site was cloned immediately downstream of luciferase in the 
pMiReport vector as previously described 14.  For S1pr1 rescue experiments, S1PR1 lacking its 3’UTR was 
cloned into the MSCV-eGFP vector.  A gRNA targeting Cas9 to the miR-125b binding site in S1PR1 3’UTR 
was cloned into a retroviral vector bearing cyan fluorescent protein (CFP). 
Cell culture  
Cells were cultured in a sterile incubator that was maintained at 37°C and 5% CO2. HEK293T cells were 
cultured in DMEM supplemented with 10% FBS, 100 U/ml penicillin, and 100 U/ml streptomycin.  
Labeling of bone marrow sinusoidal and parenchymal B cells 
To detect bone marrow sinusoidal and parenchymal B cells, we adapted an in vivo labeling procedure as 
previously described 4. Eμ/miR-125b Tg mice and littermate controls were injected intravenously with 1 μg of 
PE-conjugated anti-CD45.2 antibody in 200 μL PBS for 2 min. The mice were then immediately euthanized and 
the cells were collected from bone marrow and analyzed by flow cytometry. 
Flow cytometry  
Respective tissue samples were collected from the appropriate mice as indicated in the text and processed as 
previously described 14 (detailed in supplemental methods). 
Epigenetic Analysis 
The epigenetic analysis was described previously 15. See the supplemental Methods for detailed experimental 
setup and data analysis. 
Statistical analysis 
All statistical analysis was done in GraphPad Prism software using an unpaired Student’s t-test. Data were 
reported as mean ± SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001; NS, not significant. 
Accession number 
All sequencing data are available in the NCBI’s Gene Expression Omnibus (GEO) database under the accession 
number GSE82144. 
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RESULTS 
Epigenetic regulation of miR-125b expression in B cells 
To investigate the role of miR-125b in B cells, we first examined its expression in mouse spleen and bone 
marrow cells as well as various types of immune cells.  We found that the expression of miR-125b-5p and 3p 
(two mature microRNAs originating from opposite arms of the same miR125b-1 pre-miRNA) was much higher 
in macrophages compared with other immune cells and tissues.  In contrast, purified splenic B cells expressed 
an extremely low level of both miR-125b-5p and 3p (Figure 1A).  Further analysis of their expression in sorted 
bone marrow lineage-negative, Sca-1+, c-Kit+  (LSK) cells and B cell subset populations showed reduced 
expression of these microRNAs throughout B lymphocyte lineage differentiation (Figure 1B).  To determine 
how miR-125b expression is regulated, we examined histone modifications in the genome locus of the two 
genes encoding miR-125b by chromatin immunoprecipitation (ChIP) sequencing 15.  The promoter region of the 
miR-125b-1-encoding gene displayed a high level of the repressive modification H3K27me3 and lacked 
activating modifications including H3K14ac, H3K36ac, H3K4me3, H3K79me2 and H4K91ac.  We also 
detected no p300 or RNA polymerase II (PolII) enrichment in the promoter region, consistent with this region’s 
transcriptional silencing (Figure 1C).  In these resting B cells, the miRNA-125b-2 locus also lacked active 
modifications and p300/PolII recruitment in its promoter region, although it lacked repressive marks as well.  By 
contrast, miR-15b/16 clusters are actively expressed during lymphopoiesis and required for controlling B cell 
proliferation 16.  We confirmed that miR-15b/16 clusters displayed a high degree of activating modifications as 
well as p300 and PolII recruitment in the promoter region of their encoding gene (Figure 1C), acting as a 
control for the effectiveness of our assay.  We also examined the active modification H3K4me3 and repressive 
modification H3K27me3 in miR-125b encoding genes in pro-B cells, pre-B cells and LPS plus IL-4 activated B 
cells.  We found that these B cell subsets displayed similar histone modification patterns to those observed in 
resting B cells (Figure S1A).  Thus, these data suggest that miR-125b is epigenetically silenced as 
hematopoietic cells transition from pluripotency to differentiated B cells.   
Dysregulated miR-125b expression reduced number of B cells in the blood and spleen  
To understand the biological importance of the physiological down-regulation of miR-125b expression in B 
cells, we examined the effect of overexpression of miR-125b on B cell development using Eμ/miR-125b-Tg 
mice.  These mice overexpressed miR-125b (200-400 fold higher than the control mice) only in B lineage cells 
throughout their development (Figure S2A).  B cells (B220+) were quantified in the bone marrow, blood, 
spleen, and peripheral lymph nodes (PLNs) of wild-type (WT) and Eμ/miR-125b-Tg mice at 8 weeks of age.  A 
decreased frequency and number of B220+ B cells was evident in Eμ/miR-125b-Tg mice in all of these 
compartments, with the most striking differences evident in the blood and PLNs (Figure 2A and 2B).  This was 
accompanied by a decrease in the total number of leukocytes (CD45+) in both the blood and spleens of Eμ/miR-
125b-Tg mice.  In contrast, the number of CD4+ T lymphocytes, CD8+ T lymphocytes and CD11b+ myeloid 
cells were largely unchanged.  An even greater reduction of B cells in the blood was observed in 6-month-old 
Eμ/miR-125b-Tg mice (Figure 2B). 
For personal use only.on March 27, 2018. by guest  www.bloodjournal.orgFrom 
                                                            Li et al. – Mir-125b and B cells 
Page 6 of 17. 
To better understand the role of miR-125b in early B cell commitment, we analyzed the B cell precursor 
cells [Hardy fractions 17] in the bone marrow of WT and Eμ/miR-125b-Tg mice (Figure 3A).  Eμ/miR-125b-Tg 
mice revealed a comparable frequency and number of precursor-progenitor B (pre/pro-B) and pro-B cells 
(Hardy Fr.ABC), but a significant decrease in pre-B cells (Hardy Fr.D) (Figure 3B).  Interestingly, immature B 
cells (Hardy Fr.E) are comparable in WT and Eμ/miR-125b-Tg mice, while the number of recirculating mature 
B cells (Hardy Fr.F) is slightly reduced in Eμ/miR-125b-Tg mice (Figure 3B).  The peripheral blood normally 
contains immature B cells recently released from the bone marrow along with recirculating mature B cells.  We 
found that Eμ/miR-125b-Tg mice had a significant reduction in the frequency and total number of both 
peripheral blood and splenic immature and mature B cells compared with WT controls (Figure 3C and S3A).  
Similar results were obtained with B cell maturation markers CD93 and CD62L.  Particularly, the number of 
immature B cells was dramatically reduced in Eμ/miR-125b-Tg mice (Figure 3C, 3D, S3B and S3C).  Thus, 
dysregulated miR-125b expression reduces B cell numbers in the blood and spleen as well as pre-B cell numbers 
in the bone marrow, providing an explanation for why miR-125b is so effectively suppressed in normal B-
lineage cells.  
Dysregulated miR-125b expression impaired egress of immature B cells 
The reduction in B-cell number observed in peripheral blood of Eμ/miR-125b-Tg mice could be because of 
reduced proliferation, increased apoptosis and/or inefficient release of newly formed B cells from bone marrow 
to peripheral blood.  In vivo analysis of the proliferation of B-cell progenitors in the bone marrow after BrdU 
incorporation did not reveal any significant difference between Eμ/miR-125b-Tg and control mice (Figure 4A). 
Once immature B cells leave the bone marrow parenchyma, they enter and then are temporarily retained in the 
sinusoidal vasculature before finally being released into peripheral blood.  To enumerate the bone marrow 
sinusoidal B cells, we used anti-CD45.2-PE injection to label B cells present within sinusoids 2,4. We found a 
significantly lower number of immature B cells (B220+IgM+IgD-CD45.2+) in the sinusoids of Eμ/miR-125b-Tg 
mice (Figure 4B, upper panel). A reduction of immature B cells in the sinusoids may be due to defective 
migration from the parenchyma, which would result in an increased number of total immature B cells in the 
parenchyma.  However, the number of parenchymal immature B cells (B220+IgM+IgD–CD45.2–) is comparable 
in the Eμ/miR-125b-Tg and control mice (Figure 4B, lower panel), suggesting no accumulation of bone 
marrow immature B cells in the parenchyma of Eμ/miR-125b-Tg mice.  We next tested if the inappropriately 
retained cells in bone marrow because of an exit defect might instead undergo apoptosis.  By using annexin V 
staining to assess the apoptosis of the pro–/pre– and immature B cells in the bone marrow of Eμ/miR-125b-Tg 
mice, we found that the annexin V+ pro–/pre–B cell fraction was similar in Eμ/miR-125b-Tg and control mice.  
However, the immature B cell population showed significantly more annexin V+ staining in Eμ/miR-125b-Tg 
mice than control mice, indicating an increased incidence of cell death (Figure 4C and S4A). 
Interaction of chemokine (C-X-C motif) receptor 4 (CXCR4) with its ligand SDF-1 is required for bone 
marrow retention of developing B cells in the parenchyma 2-4,18.  When control mice were treated with 
AMD3100, a potent CXCR4 antagonist, immature bone marrow B cells (B220+ CD93+), CD3+ T lymphocytes 
and CD11b+ myeloid cells were released into peripheral blood (Figure 4D).  The release of immature B cells 
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into the blood was significantly lower in Eμ/miR-125b-Tg mice than in control mice after AMD3100 treatment, 
suggesting that miR-125b still inhibited B cell release from the bone marrow even when CXCR4 signaling was 
attenuated.  Taken together, these findings indicate that dysregulated miR-125b expression causes the retention 
of immature B cells inside bone marrow sinusoids, leading to an increase in apoptosis.  
Sphingosine-1-phosphate receptor 1 (S1PR1) is a direct target of miR-125b 
We next sought to better understand the underlying molecular mechanism for the defect in B cell egress in 
Eμ/miR-125b-Tg mice.  In a computational online search with TargetScan/MicroRNA, we identified a potential 
target of miR-125b, S1PR1, which is a key regulator of the process of immature B cell release from the bone 
marrow 2-4,19 (Figure 5A).  RNA was extracted from bone marrow B220+ B cells of Eμ/miR-125b-Tg and 
control mice and then subjected to quantitative polymerase chain reaction (qPCR) to examine the effect of miR-
125b on S1PR1 expression.  We found significantly reduced S1PR1 mRNA expression levels in dysregulated 
miR-125b-expressing B cells compared with controls (Figure 5B).  In contrast, the expression of S1PR2 and 
S1PR3, two other members in the S1P receptor family that lack a miR-125b binding site in their 3’ UTR, 
remained unchanged.  We next determined whether S1PR1 might represent a direct target of miR-125b by 
performing luciferase assays as previously described 20.  A luciferase reporter, in which the S1PR1 3’UTR was 
placed immediately downstream of luciferase, was transfected into HEK293 cells with either the miR-125b or a 
control vector.  Overexpression of miR-125b significantly reduced luciferase activity, indicating the S1PR1 
3’UTR is a direct target (Figure 5C).  We next quantified S1pr1 protein expression in B cells from Eμ/miR-
125b-Tg and control mice.  Consistent with S1PR1 being a target of miR-125b, we found protein expression 
was significantly downregulated in B cells with dysregulated miR-125b expression (Figure 5D and S5A).  In 
addition to CXCR4 signaling, the exit of immature B cell from bone marrow also relies on egress-promoting 
activity of S1P and S1PR1, which were thought to provide release signals for immature B cells 2,5.  We next 
investigated if S1PR1 is the key target of miR-125b responsible for regulating B cell egress.  To do this, we 
attempted to rescue the defect in B cell exit observed in Eμ/miR-125b-Tg mice by expressing S1PR1 that lacked 
the miR-125b-binding site.  Hematopoietic stem/progenitor cells (HSPCs) from WT and Eμ/miR-125b-Tg were 
transduced with either a control vector (MSCV) or a S1PR1 expressing vector (MSCV-S1PR1) lacking the 
S1PR1 3’UTR, and were then subsequently used to reconstitute lethally irradiated WT mice (Figure S5B).  We 
first validated the expression of S1PR1 in the respective samples by RT-qPCR (Figure S5C).  Analysis of the 
peripheral blood of mice at 7 weeks after reconstitution revealed that expression of S1PR1 partially rescues the 
loss of peripheral B cells observed with dysregulated miR-125b expression (Figure 5E).   
We further attempted to genetically disrupt the miR-125b targeting site in 3’UTR of S1PR1 using the 
CRISPR/Cas9 system to see if it would rescue such a defect.  We designed a gRNA to target Cas9 to miR-125b 
binding site in S1PR1 3’UTR and this gRNA was cloned into a retroviral vector bearing cyan fluorescent 
protein (CFP) (Figure 5F and S5D).  To test the efficiency of the gRNA, we infected HSPCs with retroviruses 
to deliver the gRNA into cells and performed a surveyor assay (a mismatch cleavage assay) to measure the 
insertions/deletions (indels) at the S1PR1 3’UTR locus 21. Efficient editing in the UTR locus was observed 
(Figure 5G).  Sequencing confirmed that this gRNA efficiently induced indel mutations (Figure S5E).  To track 
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the reconstitution with bone marrow-derived elements, we next reconstituted recipient C57BL/6 mice (CD45.1) 
with HSPCs from Cas9 Tg (CD45.2) or Eμ/miR-125b-Cas9 Tg (CD45.2) mice, which were transduced with a 
vector expressing a control gRNA, or a vector expressing S1PR1 3’UTR targeting gRNA (Figure S5F).  Flow 
cytometric analysis was performed to examine the B cell egress 7 weeks after reconstitution of recipient mice 
with sorted CFP+ bone marrow cells.  We found a significant increase in total B cells (B220+) in the mice 
reconstituted with HSPCs expressing S1PR1 3’UTR-targeting gRNA compared with the mice reconstituted with 
HSPCs expressing control gRNA (Figure 5H).  These results demonstrate a specificity of miR-125b targeting 
for S1PR1 in B cell egress. 
IRF4 is a suppressor of miR-125b induced B cell leukemia 
Along with impaired output of pre-B cell and impaired immature B cell egress, transgenic miR-125b expression 
causes lymphoblastic leukemia in mice 7,8,11. Our lab has previously found that miR-125b dysregulation-induced 
BCP-ALL displays a genetic deletion of the gene encoding IRF4 11.  However, whether IRF4 plays a role in 
oncogenic miR-125b-induced B cell transformation is still unknown.  To test this possibility, we bred B cell-
specific IRF4 deficient (CD19cre IRF4flox/flox) mice with the Eμ/miR-125b-Tg mice and generated IRF4 
homozygous mutant mice expressing the Eμ/miR-125b transgene (Double Tg).  The effect of IRF4 deletion on 
tumorigenesis of Eμ/miR-125b-Tg mice was monitored for a period of 12 months.  At 20 weeks of age, 
Eμ/miR-125b-Tg mice and CD19cre IRF4flox/flox mice were healthy and displayed no signs of B cell leukemia in 
Wright's-stained blood smears (data not shown).  Five of 20 monitored Eμ/miR-125b-Tg mice and nine of 24 
CD19cre IRF4flox/flox mice developed B-cell cancer with a long latency and were found moribund starting from 
the age of 6 months (Figure 6A and 6B).  In contrast, double Tg mice showed a dramatically accelerated 
mortality with a median age of 3 months, and all of them died within 4 months (Figure 6A and 6B).  At as early 
as 5 weeks of age, some double Tg mice already displayed massively enlarged spleens, while this was not 
evident in the Eμ/miR-125b-Tg mice and CD19cre IRF4flox/flox mice of the same age (Figure S6A).  Flow 
cytometry results confirmed the presence of massive numbers of B-lymphocytes in all moribund Tg mice 
compared with control mice (Figure S6B).  This phenotype was indicative of precursor B-cell leukemia as 
evidenced by the lack of CD43, IgM and IgD expression (Figure 6C and S6C).  These B cell tumors were 
clonal in origin as suggested by the specific rearrangements of the VDJ region of the immunoglobulin heavy 
chain locus (Figure S6D). To determine if the leukemic B cells derived from these Tg mice are transplantable, 
we injected bone marrow cells of moribund mice into irradiated secondary recipients.  The recipient mice were 
all moribund two months after transplantation and developed B cell leukemia characterized by splenomegaly 
and domination of B220+ cells in the peripheral blood and spleen (Figure 6D, 6E and S6E).  We next 
investigated whether delivering IRF4 without its 3’UTR to bone marrow cells from Eμ/miR-125b Tg mice could 
prevent B cell leukemia.  To do this, we reconstituted lethally irradiated WT C57BL/6 mice with HSPC-
enriched bone marrow cells from Eμ/miR-125b-Tg mice that were transduced with either a control vector or an 
IRF4 expressing vector.  Over the course of 1 year, about 20% of mice that received Eμ/miR-125b-Tg donor 
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cells expressing the control vector developed spontaneous B cell cancer and succumbed to disease, while mice 
that received Eμ/miR-125b-Tg donor cells transduced with an IRF4 expression vector showed no sign of cancer 
and had a normal frequency of B220+ B cells like that found in alive control mice (Figures 6F and S6F).  This 
result suggests that IRF4 is a suppressor of miR-125b induced B cell leukemia.   
For personal use only.on March 27, 2018. by guest  www.bloodjournal.orgFrom 
                                                            Li et al. – Mir-125b and B cells 
Page 10 of 17. 
DISCUSSION 
Dysregulated miR-125b expression has been found in myeloid and B-cell leukemia.  In this study, we have 
provided evidence for a deleterious role of miR-125b expression in the B cell lineage and uncovered the 
mechanism underlying tumorigenesis and impaired immature B cell egress from bone marrow.  We showed that 
the expression of miR-125b is epigenetically silenced during the development of normal B cells.  Unregulated 
miR-125b expression leads to inefficient appearance of immature B cells in peripheral blood and also induces 
pre-B cell leukemia.  The mechanism by which miR-125b is deleterious to B cell production clearly involves at 
least its effect on S1PR1, a previously unappreciated target for miR-125b affecting B cell egress.  In addition, 
miR-125b dysregulation leads to a pro-oncogenic state that becomes evident when an IRF4 deletion occurs, 
showing that the pro-oncogenic state is controlled by IRF4.  Thus, our previous observation that the tumors in 
mice overproducing miR125b have suffered deletions of their IRF4 gene is explained by the tumor-suppressive 
ability of IRF4.  Our study has established that dysregulated expression of miR-125b functions as a critical 
inhibitor of B cell lymphopoiesis and also acts as an oncomiR to drive B cell tumorigenesis in a manner that can 
be suppressed by IRF4.  
        MiR-125b exhibits minimal expression in B cells relative to macrophages.  Profiling of the expression of 
miR-125b in LSK cells and B cell progenitors showed that expression of this microRNA is evident in 
multipotent progenitors but is silenced as cells differentiate through most of the B lymphocyte lineage, despite a 
slightly increased expression of miR-125b at the pre-B cell stage.  Some of the epigenetic, transcriptional, and 
posttranscriptional mechanisms have been suggested to help orchestrate cellular abundance of miRNAs during 
lymphopoiesis 15.  Indeed, we found that low expression of miR-125b is associated with the enrichment of 
repressive histone modification and/or the absence of active histone modifications in their respective promoter 
regions of coding genes, suggesting a tightly controlled epigenetic regulatory machinery is involved in silencing 
miR-125b during B cell development.  
To determine whether the epigenetic silencing of miR-125b has functional relevance in B cells, we 
examined its effect on the regulation of B cell lymphopoiesis.  Consistent with previous findings 11,14, we 
observed fewer pre-B cells in Eμ/miR-125b Tg mice.  Surprisingly, the development of immature B cells was 
largely unaffected, recalling the published observation that E12 deficient mice exhibit reduced pre-B cell 
numbers while immature B cell numbers remain unchanged 22.  However, in the presence of overexpressed miR-
125b, immature cells fail to be efficiently released from bone marrow and appear to undergo increased apoptosis 
in the vascular compartment of bone marrow.  It is likely that the blockage of immature B cell release backs up 
immature B cell in the bone marrow.  Developing B cells are known to be very sensitive to apoptosis 2.  The 
increased apoptotic immature B cells observed in the bone marrow of Eμ/miR-125b Tg mice may result from 
inappropriate retention of these cells within the sinusoid.  The deficiency of B cells in the spleen and PLNs 
would then be explained by the inefficient release of newly formed immature B cells.  CXCR4 plays an 
important role in regulating homeostasis of the B cell compartmentalization and is required for retention of B 
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cell precursors in the bone marrow 3.  We found that AMD3100, a specific inhibitor of CXCR4, stimulated the 
release of B cell precursors from bone marrow in control mice but not in Eμ/miR-125b Tg mice, excluding the 
possibility that inefficient B cell egress in Tg mice is due to disruption of CXCR4-mediated retention. 
Searching for a mechanism by which miR-125b exerts its effect on the B cell egress, we found that the 
direct target of miR-125b, S1PR1, is a key regulator of the process of immature B cell release from the bone 
marrow.  We found that enforced expression of S1PR1 in donor cells from Eμ/miR-125b Tg mice almost 
restored normal B cell egress, suggesting that S1PR1 is a critical target of miR-125b in regulating immature B 
cell release in Eμ/miR-125b Tg mice.  The CRISPR/Cas9 system can be used to edit mammalian germline 
sequences and cell lines 23,24.  To exclude the possibility that S1PR1 replenishes the immature B cell pool in 
peripheral blood through an indirect mechanism unrelated to the function of miR-125b in B cells, we used 
CRISPR/Cas9-mediated genome engineering technology to edit out the miR-125b binding site in the S1PR1 
3’UTR, preventing targeting by miR-125b.  Notably, we were able to partially rescue the defect of B cell egress 
upon target-editing of the miR-125b-binding site in the cells from Eμ/miR-125b Tg mice.  Our data suggests 
that S1PR1 is one of the critical targets of miR-125b in regulating immature B cell release from bone marrow in 
Eμ/miR-125b Tg mice.  Some other targets of miR-125b might also contribute to the reduced total B cell 
numbers in the periphery of the Tg mice. BCL2, which can protect against apoptosis and is required for cell 
cycle entry and proliferation, was previously identified as a target for miR-125b 25.  We found its expression was 
downregulated in B cells from Eμ/miR-125b Tg mice (Figure S5G).  In addition, the expression of E2F2, a 
potential miR-125b targeting gene that is critical for cell cycle transition 26, was also reduced in the B cells from 
Eμ/miR-125b Tg mice.  Downregulation of these genes might have an important role in B cell survival and 
proliferation in the periphery of Eμ/miR-125b Tg mice, especially when peripheral B cells encounter antigens.  
Thus, downregulation of S1PR1, BCL2 and E2F2 in B cells with dysregulated miR-125b expression could all 
contribute to the peripheral B cell deficiency in Eμ/miR-125b Tg mice. 
Overexpression of miR-125b in mice initially reduced pre-B cell output, but later induced pre-B cell 
lymphoma/leukemia, with acquisition of a genetic deletion of the tumor suppressor IRF4 gene 11,14, suggesting a 
potential role of IRF4 in miR-125b-induced B-cell cancer.  MiR-125 has been shown to target IRF4 13. 
However, we found that miR-125b has no significant impact on IRF4 expression in resting B cells (data not 
shown).  Notably, we found that miR-125b-induced acute pre-B cell leukemia was greatly accelerated in the 
IRF4 homozygous mutant mice and enforced expression of IRF4 in donor cells from Eμ/miR-125b Tg mice, 
which are prone to develop pre-B cell cancer, had a protective effect on cancer development.  This further 
suggests that genetic depletion of IRF4 makes the miR-125b-overexpressing B cells more susceptible to 
becoming cancerous.  
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 Altogether, our data supports the notion that aberrant expression of miR-125b impairs normal B cell 
development and also induces tumorigenesis, demonstrating the biological importance of the physiological 
silencing of miR-125b expression in the B cell lineage.  
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FIGURE LEGENDS 
Figure 1. Epigenetic regulation of miR-125b expression in B lymphocytes 
(A) Relative miR-125b expression in bone marrow, spleen and various immune cells.  The expression of miR-
125b-5p and miR-125b-1-3p was measured using TaqMan RT-qPCR (n=3).  (B) Relative miR-125b expression 
in HSPC (L-S+K+) cells and various B lymphocyte subsets.  (C) Modification patterns of H3K14Ac, H3K36Ac, 
H3K4me3, H3K79me2, H4K91ac, and H3K27me3, as well as polII and p300 recruitment in the loci encoding 
miR-125b and miR-15a/16-1 in resting mature B cells. 
Figure 2. Reduced number of B cells in peripheral tissues of Eμ/miR-125b Tg mice. 
(A) Frequency of B220+ B cells in peripheral tissues from 8-week old Eμ/miR-125b Tg and control mice. 
Lymphocytes from the bone marrow, peripheral blood, spleens, and PLNs from control and Eμ/miR-125b Tg 
mice were analyzed by flow cytometry.  (B) Total number of leukocytes (CD45+) and B cells (B220+), T cells 
(CD4+ or CD8+) or myeloid cells (CD11b+) counted in each organ or per microliter of peripheral blood.  Bars 
represent mean values of pooled data.  Data are pooled from two to three experiments and represented as mean ± 
SEM (n=10-12 mice per group).    
Figure 3.  Reduced number of immature B cells in the blood of Eμ/miR-125b Tg mice.   
(A) Representative flow cytometric analysis of Hardy fractions for B cell progenitor subpopulations in the bone 
marrow of 8-week old Eμ/miR-125b Tg and control mice. Hardy fractions in bone marrow (A–F) were gated as 
follows: Fr. A (Prepro-B cell; B220+CD43+BP-1−CD24−); Fr. BC (pro-B cells; B220+CD43+BP-1−CD24+ and 
B220+CD43+BP-1+CD24+); Fr. D, (pre-B cells; B220+CD43−IgM−IgD−); Fr. E (immature B cell; 
B220+CD43−IgM+IgD-); and Fr. F (mature B cells; B220+CD43−IgM+IgD+); the C′ fraction (B220+CD43+BP-
1+CD24hi) was not resolved.  (B) The frequency and number of each B-cell subpopulation in Eμ/miR-125b Tg 
and control mice.  (C) Representative flow cytometric analysis of immature and mature B cell populations in 
peripheral blood of 8-week old Eμ/miR-125b Tg and control mice.  Immature B cells were identified as B220+ 
IgDlow IgMhigh, B220+ CD93+ and B220+ CD62Llow and mature B cells were identified as B220+ IgDhigh IgMlow, 
B220+ CD93− and B220+ CD62Lhigh.  (D) The number and frequency of immature B cells (B220+ CD93+) in the 
blood of Eμ/miR-125b Tg and control mice.  Bars represent mean values of pooled data.  Data are pooled from 
two to three experiments and represented as mean ± SEM (n=8 mice per group). 
Figure 4. Impaired release of immature B cells in Eμ/miR-125b Tg mice 
 (A) Normal proliferation of bone marrow B cells in Eμ/miR-125b Tg mice.  8-week old Eμ/miR-125b Tg and 
control mice were injected with BrdU for 48 hr.  Bone marrow cells from these mice were stained with anti-
B220 antibodies in combination with BrdU detection methodology.  Percentages in the bar graph indicate BrdU-
positive cells in the gated B200+ cell subpopulations.  (B) Distribution and number of the indicated B-lineage 
populations in the bone marrow parenchyma (CD45.2−) and sinusoids (CD45.2+) of 8-week old Eμ/miR-125b 
Tg and control mice.  (C) Representative flow cytometric analysis of bone marrow B cells for staining of 
apoptotic B cell using anti-annexin-V and 7-AAD.  (D) Number of total B cells (B220+), immature B cells 
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(B220+ CD93+), T cells (CD3+) and myeloid cells (CD11b+) in 300 microliters of blood from Eμ/miR-125b Tg 
and control mice that were injected with the AMD3100 or PBS alone (n=5 mice per group).  
Figure 5. MiR-125b inhibits B cell release from bone marrow through direct targeting of S1PR1 
(A) Schematic representation of S1PR1 3’UTR showing the conserved miR-125b seed region.  (B) S1PR1 
transcript expression levels in B cells purified from the bone marrow of Eμ/miR-125b Tg and control mice.  (C) 
Relative luciferase expression in HEK293T cells transfected with luciferase reporter construct bearing S1PR1 3’ 
UTR immediately downstream (S1PR1UTR) and either a miR-125b overexpression vector (MG-125b) or a 
control vector (MG).  (D) S1pr1 protein expression levels in B cells purified from the bone marrow of Eμ/miR-
125b Tg and control mice.   Data represents two independent experiments. (E) Enumeration of B cells (B220+) 
and immature B cells (B220+ CD93+) in peripheral blood of reconstituted mice at 7 weeks after reconstitution 
(n=10 mice per group).  (F) Schematic representation of sgRNA target (red) and PAM (green) sequence 
designed to edit genomic sequence in the mouse S1PR1 3’UTR locus.  (G) Detection of genome editing in the 
S1PR1 3’UTR locus using a surveyor assay. (H) Enumeration of B cells (B220+) in peripheral blood of 
reconstituted mice at 7 weeks after reconstitution with CRISPR/Cas9-edited HSPCs (n=10-12 mice per group).  
Data represents two independent experiments and is represented as mean ± SEM.  
Figure 6. MiR-125b-induced B cell leukemia is accelerated in IRF4 deficient mice and enforced 
expression of IRF4 inhibits miR-125b-induced development of spontaneous B cell cancers in 
mice.  
(A) Survival curve of Eμ/miR-125b Tg mice, CD19cre IRF4flox/flox Tg mice, double Tg mice and control mice. 
The genotypes and number of mice in each group are indicated on the plot.  (B) Some Tg mice developed 
lymphoma.  Lymphomas are shown at the superficial cervical or inguinal lymph node sites by red arrows.   (C) 
Representative flow cytometric analysis of leukemic B cells in the blood, bone marrow and spleen of moribund 
Eμ/miR-125b, CD19cre IRF4flox/flox and double Tg mice.  (D) Survival curve of the secondary recipient mice 
transplanted with bone marrow cells from moribund Eμ/miR-125b Tg mice, CD19cre IRF4flox/flox Tg mice, 
double Tg mice and control mice (n=6 mice per group).  (E) Spleen weight of the secondary recipients described 
in panel D.  (F) Frequency of bone marrow B cells (B220+) in the mice receiving Eμ/miR-125b Tg donor cells 
that were transduced with either an IRF4 expressing vector or a control vector. 
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